Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques

AIDS Research and Human Retroviruses

Volumn 12, Issue 11, 1996, Pages 985-992

  Myagkikh, Maria ^a   Alipanah, Shabnam ^a   Markham, Phillip D ^b   Tartaglia, James ^c   Paoletti, Enzo ^c   Gallo, Robert C ^a,d   Franchini, Genoveffa ^a   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c Virogenetics Corporation   (United States)

^d INSTITUTE OF HUMAN VIROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; NEUTRALIZING ANTIBODY; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOPROPHYLAXIS; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RHESUS MONKEY; VIRUS RECOMBINANT;

EID: 0029738221     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.985     Document Type: Article

References (40)

1. Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, Davis SW, van der Hoeven J, Meignier B, Riviere M, Languet B, and Paoletti E: NYVAC: A highly attenuated strain of vaccinia virus. Virology 1992;188:217-232.
2. Tartaglia J, Taylor J, Cox WI, Audonnet J-C, Perkus ME, Paoletti E, Radaelli A, de Giuli Morghen C, Meignier B, Riviere M, and Weinhold KJ: Novel poxvirus strains as research tools and vaccine vectors. In: AIDS Research Reviews (Koff WC, Wong-Staal F, and Kennedy RC, eds.), Vol. 3. Marcel Dekker, New York, 1993, pp. 361-378.
3. Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, and Plotkin S: Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992;339:1429-1432.
4. Cox WI, Tartaglia J, and Paoletti E: Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein. Virology 1993;195:845-850.
5. Taylor J, Tartaglia J, Moran T, Webster RG, Bouquet J-R, Quimby FW, Holmes D, Laplace E, Mickle T, and Paoletti E: The role of poxvirus vectors in influenza vaccine development. In: Proceedings of the Third International Symposium on Avian Influenza. University of Wisconsin-Madison Extension Duplicating Services, Madison, Wisconsin, 1992, pp. 311-335.
6. Taylor J, Weinberg R, Tartaglia J, Richardson C, Alkhatib G, Briedis D, Appel M, Norton E, and Paoletti E: Nonreplicating viral vectors as potential vaccines: Recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992;187:321-328.
7. Konishi E, Pincus S, Paoletti E, Laegreid WW, Shope RE, and Mason PW: A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 1992;190:454-458.
8. Brockmeier SL, Lager KM, Tartaglia J, Riviere M, Paoletti E, and Mengeling WL: Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet Microbiol 1993;38:41-58.
9. Tartaglia J, Jarrett O, Neil JC, Desmettre P, and Paoletti E: Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 1993;67: 2370-2375.
10. Franchini G, Tartaglia J, Markham P, Benson J, Fullen J, Wills M, Arp J, Dekaban G, Paoletti E, and Gallo RC: Highly attenuated HTLV type I env poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits. AIDS Res Hum Retroviruses 1995;11:307-313.
11. Franchini G, Robert-Guroff M, Tartaglia J, Aggarwal A, Abimiku A, Benson J, Markham P, Limbach K, Hurteau G, Fullen J, Aldrich K, Miller N, Sadoff J, Paoletti E, and Gallo RC: Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant salmonella vaccines, induce long lasting protection in rhesus macaques. AIDS Res Hum Retroviruses 1995;11:909-920.
12. Abimiku AG, Franchini G, Tartaglia J, Aldrich K, Myagkikh M, Markham PD, Chong P, Klein M, Kieny M-P, Paoletti E, Gallo RC, and Robert-Guroff M: HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Med 1995;1:321-329.
13. Egan MA, Pavlat WA, Tartaglia J, Paoletti E, Weinhold KJ, Clements ML, and Siliciano RF: Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range, restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 1995;171:1623-1627.
14. Pialoux G, Excler J-L, Riviere Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman J-C, Matthews TJ, Meignier B, Kieny M-P, Gonnet P, Diaz I, Meric C, Paoletti E, Tartaglia J, Salomon H, Plotkin S, the Agis Group, and L'Agence Nationale de Recherche sur le SIDA: A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 1995;11:373-381.
15. Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven K, Franchini G, Trimarchi C, and Paoletti E: Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 1995;13:539-549.
16. Gonczol E, Berericsi K, Meric C, Endresz V, Jourdier TM, Pincus S, Cox W, Kauffman E, Meignier B, Paoletti E, and Plotkin SA: Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 1995;13: 1080-1085.
17. Robert-Guroff M: Neutralizing antibodies. In: Techniques in HIV Research (Aldovini A and Walker BD, eds.). Stockton Press, New York, 1990, pp. 179-185.
18. Takahashi H, Cohen J, Hosmalin A, Cease KB, Houghten R, Cornette JL, DeLisi C, Moss B, Germain RN, and Berzofsky JA: An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988;85:3105-3109.
19. Achour A, Picard O, Zagury D, Sarin PS, Gallo RC, Naylor PH, and Goldstein AL: HGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals. Proc Natl Acad Sci USA 1990;87:7045-7049.
20. Yamamoto H, Miller MD, Tsubota H, Watkins DI, Mazzara GP, Stallard V, Panicali DL, Aldovini A, Young RA, and Letvin NL: Studies of cloned simian immunodeficiency virus-specific T lymphocytes: gag-specific cytotoxic T lymphocytes exhibit a restricted epitope specificity. J Immunol 1990;144:3385-3391.
21. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallwey J, and McMichael AJ: HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature (London) 1988;336:484-487.
22. Cease KB, Margalit H, Cornette JL, Putney SD, Robey WG, Ouyang C, Streicher HZ, Fischinger PJ, Gallo RC, DeLisi C, and Berzofsky JA: Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide. Proc Natl Acad Sci USA 1987;84: 4249-4253. [Published erratum appears in Proc Natl Acad Sci USA 1988 Nov;85(21):8226]
23. Biberfeld G, Andersson S, Putkonen P, Thorstensson R, Makitalo B, Gilljam G, Franchini G, Tartaglia J, and Paoletti E: Protective immunity in cynomolgus monkeys immunized with canary pox HIV-2 vaccines and/or HIV-2 gp125. AIDS Res Hum Retroviruses 1994;10(Suppl. 3):S116. [Abstract]
24. Biberfeld G, Thorstensson R, and Putkonen P: Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2. AIDS Res Hum Retroviruses 1996 (in press).
25. Giavedoni LD, Planelles V, Haigwood NL, Ahmad S, Kluge JD, Marthas ML, Gardner MB, Luciw PA, and Yilma TD: Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol 1993;67:577-583.
26. Daniel MD, Mazzara GP, Simon MA, Sehgal PK, Kodama T, Panicali DL, and Desrosiers RC: High-liter immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res Hum Retroviruses 1994;10:839-851.
27. Hu S-L, Abrams K, Barber GN, Moran P, Zarling JM, Langlois AJ, Kuller L, Morton WR, and Benveniste RE: Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992;255:456-459.
28. Vogt G, le Grand R, Vaslin B, Boussin F, Auboyer M-HB, Riviere Y, Putkonen P, Sonigo P, Kieny M-P, Girard M, and Dormont D: Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins. Vaccine 1995;13:202-208.
29. Israel ZR, Edmonson PF, Maul DH, O'Neil SP, Mossman SP, Thiriart C, Fabry L, Van Opstal O, Bruck C, Bex F, Burny A, Fultz PN, Mullins JI, and Hoover EA: Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol 1994;68:1843-1853.
30. Putkonen P, Thorstensson R, Ghavamzadeh L, Albert J, Hild K, Biberfeld G, and Norrby E: Prevention of HIV-2 and SIVsm infection by passive immunization in cynomolgus monkeys. Nature (London) 1991;352:436-438.
31. Putkonen P, Bjorling E, Akerblom L, Thorstensson R, Lovgren K, Benthin L, Chiodi F, Morein B, Biberfeld G, Norrby E, and Wigzell H: Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 ISCOM vaccine. J Acquir Immune Defic Syndr 1994;7:551-559.
32. Stahl-Hennig C, Coulibaly C, Petty H, Voss G, Dittmer U, Bodemer W, Makoschey B, Jurkiewicz E, Luke W, and Hunsmann G: Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo. AIDS Res Hum Retroviruses 1994;10:S27-S32.
33. Luke W, Voss G, Stahl-Hennig C, Coulibaly C, Putkonen P, Petry H, and Hunsmann G: Protection of cynomolgus macaques (Macaca fascicularis) against infection with the human immunodeficiency virus type 2 strain ben (HIV-2ben) by immunization with the virion-derived envelope glycoprotein gp130. AIDS Res Hum Retroviruses 1993;9:387-394.
34. Putkonen P, Nilsson C, Walther L, Ghavamzadeh L, Hild K, Broliden K, Biberfeld G, and Thorstensson R: Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys. J Med Primatol 1994;23:89-94.
35. Putkonen P, Thorstensson R, Cranage M, Nilsson C, Ghavamzadeh L, Albert J, Greenaway P, and Biberfeld G: A formalin inactivated whole SIVmac vaccine in ribi adjuvant protects against homologous and heterologous SIV challenge. J Med Primatol 1992;21: 108-112.
36. Desrosiers RC, Wyand MS, Kodama T, Ringler DJ, Arthur LO, Sehgal PK, Letvin NL, King NW, and Daniel MD: Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci USA 1989;86:6353-6357.
37. Murphey-Corb M, Martin LN, Davison-Fairburn B, Montelaro RC, Miller M, West M, Ohkawa S, Baskin GB, Zhang J-Y, Putney SD, Allison AC, and Eppstein DA: A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 1989;246:1293-1297.
38. Carlson JR, McGraw TP, Keddie E, Yee JL, Rosenthal A, Langlois AJ, Dickover R, Donovan R, Luciw PA, Jennings MB, et al.: Vaccine protection of rhesus macaques against simian immunodeficiency virus infection. AIDS Res Hum Retroviruses 1990;6: 1239-1246.
39. Hulskotte EGJ, Geretti A-M, Siebelink KHJ, van Amerongen G, Cranage MP, Rud EW, Norley SG, De Vries P, and Osterhaus ADME: Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5). J Virol 1995;69:6289-6296.
40. Hu S-L, Stallard V, Abrams K, Barber GN, Kuller L, Langlois AJ, Morton WR, and Benveniste RE: Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160. J Med Primatol 1993;22:92-99.